2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses single-agent immunotherapy in acute myeloid leukemia.
Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses single-agent immunotherapy in acute myeloid leukemia (AML).
Although single agent PD-1 inhibition has not shown activity in AML, single agent CTLA-4 inhibition may have a role, says Daver. For example, promising data has been shown with ipilimumab (Yervoy) as a single agent in patients with AML.
Not all checkpoint inhibitors are equal, says Daver, and combinations will likely be the future of immunotherapy in AML.